Predictive inference for clinical trials with the parametric bootstrap
Predictive inference for clinical trials with the parametric bootstrap
批准号:
2565020
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
尖端医疗的发展需要有针对性的统计方法来分析临床试验数据。在这一领域,许多令人感兴趣的问题都有一种独特的因果关系。随着时间的推移,新药或疫苗对患者结局的预期效果是什么?这种影响在不同的人口亚群中有何不同?通过结合观察数据或历史数据,这些结论能得到强化吗?显然,21世纪的生物医学研究需要在因果推理领域取得深思熟虑和原创性的进展。本项目的总体目标是在贝叶斯框架内发展预测推理的理论和实践,作为解决这些问题的一种新颖和独特的方法。给定未知参数抽样分布的观测数据,标准的贝叶斯方法将得到先验密度和似然函数,然后推导后验密度。然而,预测性方法指出,这一后验数据中的统计不确定性完全是因为我们只能观察到有限的数据样本,因此没有观察到。如果我们能观察到无限的数据,那么任何感兴趣的参数都将被完全定义。因此,另一种方法是直接对预测密度建模,然后通过Bootstrap重采样过程来计算更多的观测值,从而有效地将统计推断问题转化为丢失数据问题。这种预测性重新抽样的观点提供了一个有趣的视角,通过它来观察临床试验的分析。特别是,临床试验的重点通常是治疗将如何影响患者的结果。因此,预测方法更直接地解决了这个问题,将实际的未来数据点作为推理的对象,而不是通过人为的模型构造来处理参数。贝叶斯预测推理也为不确定性量化和假设检验相关问题提供了一个新的视角。标准的频率主义假设检验可能会试图为某个估计量推导出一个密度函数,然后用它来计算可信区间和p值。相反,我们的方法再次考虑了重复采样丢失或未观察到的数据以生成几个完整数据集的概念。然后,任何假设都可以相对于从这些数据集产生的“真参数”的多元宇宙进行评估。最终结果是传统假设检验方法的无先验贝叶斯替代方法。通过我们与诺和诺德的合作,我们将把这些方法应用到现实世界的临床试验数据中,包括心脏病和糖尿病的治疗。该项目属于EPSRC研究领域“统计学和应用概率”,涉及“应用启发下的统计方法和新概率技术的发展”。它由诺和诺德共同资助,克里斯·霍姆斯教授监督,斯蒂芬·沃克教授补充合作。
英文摘要
The development of cutting-edge medical treatments requires targeted statistical methods for the analysis of clinical trial data. In this arena, many questions of interest have a distinctively causal flavor. What is the expected effect of a new drug or vaccine on patient outcomes over time? How does that effect vary across different subgroups of the population? Can these conclusions be strengthened by incorporating observational or historical data? It is clear that 21st-century biomedical research necessitates thoughtful and original advancements in the area of causal inference.The general aim of this project is to develop the theory and practice of predictive inference within a Bayesian framework as a novel and unique approach to these questions. Given observed data from an unknown parametric sampling distribution, the standard Bayesian approach would be to elicit a prior density and likelihood function, then derive the posterior density. The predictive approach, however, notes that the statistical uncertainty in this posterior arises entirely from the fact that we can only observe a limited sample of data and are therefore missing observations. If we could observe infinite data, then any parameter of interest would be fully defined. An alternative method is therefore to directly model the predictive density and then impute further observations through a bootstrap resampling procedure, effectively transforming the statistical inference problem into a missing data problem. This predictive resampling viewpoint provides an interesting lens through which to view the analysis of clinical trials. In particular, the focus of a clinical trial is generally on how the treatment will affect patient outcomes. The predictive approach therefore addresses this question more directly by taking the actual future data points as the objects of inference, rather than working through a parameter which may be an artifical model construct.Bayesian predictive inference also provides a novel perspective on questions related to uncertainty quantification and hypothesis testing. A standard frequentist hypothesis test would likely attempt to derive a density function for some estimator, then use it to calculate confidence intervals and p-values. Instead, our approach again considers the concept of sampling the missing or unobserved data repeatedly in order to generate several complete datasets. Any hypothesis can then be evaluated with respect to the multiverse of "true parameters" arising from these datasets. The final result is a prior-free Bayesian alternative to traditional methods of hypothesis testing. Through our collaboration with Novo Nordisk, we will apply these methods to real-world clinical trial data, including treatments for heart disease and diabetes.This project falls under the "Statistics and applied probability" EPSRC research area, which involves "statistical methodology and development of new probabilistic techniques inspired by applications". It is co-funded by Novo Nordisk and supervised by Professor Chris Holmes, with additional collaboration from Professor Stephen Walker.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金